Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1513||SWOG||Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1005||RTOG||A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|N0147||NCCTG||A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NHLBI-MDS||ECOG||The National Myelodysplastic Syndromes (MDS) Study||Cancer Prevention and Control CIRB||Available to Open|
|A021502||Alliance||Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC*)||Adult CIRB - Late Phase Emphasis||Available to Open|
|PEPN1812||A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND #145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|10129||ETCTN||A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|AAML0631||COG||Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND# 103; 331) during Consolidation: A Phase III Study Limited to COG institutions in the United States & Canada||Pediatric CIRB||Available to Open|
|NWU2015-06-03||CLO-Northwestern University||Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer||Cancer Prevention and Control CIRB||Available to Open|
|9837||ETCTN||Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors; with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin||Adult CIRB - Early Phase Emphasis||Available to Open|